Sign in
CompletedNo phase

Endogenous Lithium Clearance in Acute Kidney Injury

Key facts

Who runs it
University Hospital of North Norway
Where
Norway1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
1 Aug 2023
Ended
20 May 2025
Type of study
Observational, 2 groups
Treatments tested
  • Lithium clearance
Record updated
22 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • ICU patients diagnosed with AKI, without AKI and healthy controls

Who cannot take part

  • -

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Critically ill patients are at high risk of developing acute kidney injury (AKI). Lithium is freely filtrated at the glomerulus and almost completely reabsorbed in the proximal tubule, which provides a quantitative estimation of proximal tubule reabsorption. The investigators hypothesized that endogenous lithium reabsorption is impaired in the early stages of critical illness.

Read full original descriptionShow less

Investigators would like to study 10 ICU patients with AKI diagnosed, 10 patients without AKI, and 10 healthy controls.

The 2 groups in the trial

  • Group 1

    ICU patients with AKI

    Treatment: Lithium clearance

  • Group 2

    ICU patients with normal renal function

    Treatment: Lithium clearance

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
22 June 2025